89Bio

1 open jobs

89Bio is a clinical-stage biopharmaceutical company dedicated to developing therapies for patients with liver and cardiometabolic diseases, with a focus on advancing its lead candidate pegozafermin, a FGF21 analog, through Phase 3 clinical development for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia.